Efficacy and Safety of the Medium Cut-Off Elisio HX Dialyzer
© 2022 The Author(s). Published by S. Karger AG, Basel..
INTRODUCTION: The medium cut-off Elisio HX dialyzer by Nipro became commercially available in Europe in 2021, but there are still no reports of in vivo data. This study aimed to evaluate the safety and efficacy of it compared with previously evaluated hemodialysis (HD), expanded HD (HDx), and postdilution hemodiafiltration (HDF) treatments.
METHODS: A prospective study was carried out on 18 patients who underwent 5 dialysis sessions: FX80 Cordiax in HD, Elisio H19 in HD, Elisio HX19 in HDx, Theranova 400 in HDx, and FX80 Cordiax in HDF. The reduction ratios of urea, creatinine, ß2-microglobulin, myoglobin, kappa FLC, prolactin, α1-microglobulin, α1-acid glycoprotein, lambda FLC, and albumin were compared. Dialysate albumin loss was measured.
RESULTS: The comparison between the different dialysis modalities revealed no difference for small molecules, but HDx and HDF were significantly more efficient than HD for medium and large molecule removal. The efficacy of Elisio HX19 dialyzer in HDx was similar to the Theranova 400, superior to both dialyzers in HD, and slightly lower than HDF. Albumin losses in dialysate with HD dialyzers were less than 1 g, but between 1.5 and 2.5 g in HDx and HDF. The global removal score (GRS) values with HDx treatments were statistically significantly higher than those with HD. The highest GRS was obtained with the helixone dialyzer in HDF.
CONCLUSIONS: The new MCO dialyzer, Elisio HX, performs with excellent behavior and tolerance. It represents an upgrade compared to their predecessor and is very close to the removal capacity of HDF treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:52 |
|---|---|
| Enthalten in: |
Blood purification - 52(2023), 1 vom: 23., Seite 68-74 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Maduell, Francisco [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Albumins |
|---|
| Anmerkungen: |
Date Completed 31.01.2023 Date Revised 11.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1159/000524644 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340795301 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340795301 | ||
| 003 | DE-627 | ||
| 005 | 20231226010258.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000524644 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1135.xml |
| 035 | |a (DE-627)NLM340795301 | ||
| 035 | |a (NLM)35551384 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Maduell, Francisco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and Safety of the Medium Cut-Off Elisio HX Dialyzer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.01.2023 | ||
| 500 | |a Date Revised 11.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Author(s). Published by S. Karger AG, Basel. | ||
| 520 | |a INTRODUCTION: The medium cut-off Elisio HX dialyzer by Nipro became commercially available in Europe in 2021, but there are still no reports of in vivo data. This study aimed to evaluate the safety and efficacy of it compared with previously evaluated hemodialysis (HD), expanded HD (HDx), and postdilution hemodiafiltration (HDF) treatments | ||
| 520 | |a METHODS: A prospective study was carried out on 18 patients who underwent 5 dialysis sessions: FX80 Cordiax in HD, Elisio H19 in HD, Elisio HX19 in HDx, Theranova 400 in HDx, and FX80 Cordiax in HDF. The reduction ratios of urea, creatinine, ß2-microglobulin, myoglobin, kappa FLC, prolactin, α1-microglobulin, α1-acid glycoprotein, lambda FLC, and albumin were compared. Dialysate albumin loss was measured | ||
| 520 | |a RESULTS: The comparison between the different dialysis modalities revealed no difference for small molecules, but HDx and HDF were significantly more efficient than HD for medium and large molecule removal. The efficacy of Elisio HX19 dialyzer in HDx was similar to the Theranova 400, superior to both dialyzers in HD, and slightly lower than HDF. Albumin losses in dialysate with HD dialyzers were less than 1 g, but between 1.5 and 2.5 g in HDx and HDF. The global removal score (GRS) values with HDx treatments were statistically significantly higher than those with HD. The highest GRS was obtained with the helixone dialyzer in HDF | ||
| 520 | |a CONCLUSIONS: The new MCO dialyzer, Elisio HX, performs with excellent behavior and tolerance. It represents an upgrade compared to their predecessor and is very close to the removal capacity of HDF treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Dialyzer performance | |
| 650 | 4 | |a Expanded hemodialysis | |
| 650 | 4 | |a Helixone | |
| 650 | 4 | |a Hemodiafiltration | |
| 650 | 4 | |a Polyethersulfone | |
| 650 | 7 | |a Albumins |2 NLM | |
| 650 | 7 | |a Dialysis Solutions |2 NLM | |
| 700 | 1 | |a Broseta, José Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Espinosa, Diana |e verfasserin |4 aut | |
| 700 | 1 | |a Del Risco-Zevallos, Jimena |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez, Miquel |e verfasserin |4 aut | |
| 700 | 1 | |a Rodas, Lida M |e verfasserin |4 aut | |
| 700 | 1 | |a Arias-Guillén, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Vera, Manel |e verfasserin |4 aut | |
| 700 | 1 | |a Fontseré, Néstor |e verfasserin |4 aut | |
| 700 | 1 | |a Salgado, Maria Del Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Rico, Nayra |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood purification |d 1993 |g 52(2023), 1 vom: 23., Seite 68-74 |w (DE-627)NLM012656127 |x 1421-9735 |7 nnns |
| 773 | 1 | 8 | |g volume:52 |g year:2023 |g number:1 |g day:23 |g pages:68-74 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000524644 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 52 |j 2023 |e 1 |b 23 |h 68-74 | ||